Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 1/2007

01-03-2007 | Research Paper

Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells

Authors: Kathrin Rupertus, Otto Kollmar, Claudia Scheuer, Bastian Junker, Michael D. Menger, Martin K. Schilling

Published in: Clinical & Experimental Metastasis | Issue 1/2007

Login to get access

Abstract

Background

The effect of hepatectomy and hepatic regeneration on intra- and extrahepatic tumor growth is still controversially discussed. Herein we studied the effect of minor (30%) or major (70%) hepatectomy on engraftment of extrahepatic tumor cells, and the role of tumor neovascularization and tumor cell migration.

Methods

Green fluorescent protein (GFP)-transfected CT26.WT colorectal cancer cells were implanted in dorsal skinfold chambers of syngeneic BALB/c mice. Animals underwent 30% (30%Phx, n = 8) or 70% hepatectomy (70%Phx, n = 8). Sham-operated animals served as controls (n = 8). Angiogenesis and neovascularization as well as tumor cell migration, proliferation and growth were studied over 14 days using intravital fluorescence microscopy, histology and immunohistochemistry.

Results

After both minor and major hepatectomy tumor proliferating cell nuclear antigen (PCNA) expression increased significantly (P < 0.05) when compared with nonhepatectomized controls. However, only major but not minor hepatectomy accelerated neovascularization (P < 0.05) and tumor cell migration (P < 0.05). This was associated with a significantly (P < 0.05) enhanced tumor growth after 70%Phx when compared with 30%Phx and controls. The rate of apoptotic cell death was not affected by major or minor hepatectomy.

Conclusion

Regeneration after major hepatectomy accelerates extrahepatic tumor cell engraftment, most probably by acceleration of neovascularization and induction of tumor cell migration.
Literature
1.
Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30PubMedCrossRef
2.
Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H (1999) Factors influencing survival of patients undergoing hepatectomy for colorectal metastases. Br J Surg 86:332–337PubMedCrossRef
3.
Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCrossRef
4.
DeMatteo RP, Palese C, Jarnagin WR, Sun RL, Blumgart LH, Fong Y (2000) Anatomic segmental hepatic resection is superior to wedge resection as an oncologic operation for colorectal liver metastases. J Gastrointest Surg 4:178–184PubMedCrossRef
5.
Imamura H, Seyama Y, Kokudo N, Maema A, Sugawara Y, Sano K, Takayama T, Makuuchi M (2003) One thousand fifty-six hepatectomies without mortality in 8 years. Arch Surg 138:1198–1206PubMedCrossRef
6.
Jarnagin WR, Gonen M, Fong Y, DeMatteo RP, Ben-Porat L, Little S, Corvera C, Weber S, Blumgart LH (2002) Improvement in perioperative outcome after hepatic resection: analysis of 1803 consecutive cases over the past decade. Ann Surg 236:397–406PubMedCrossRef
7.
Chang YC (2004) Low mortality major hepatectomy. Hepatogastroenterology 51:1766–1770PubMed
8.
Seyama Y, Kubota K, Sano K, Noie T, Takayama T, Kosuge T, Makuuchi M (2003) Long-term outcome of extended hemihepatectomy for hilar bile duct cancer with no mortality and high survival rate. Ann Surg 238:73–83PubMedCrossRef
9.
Stewart GD, O’Suilleabhain CB, Madhavan KK, Wigmore SJ, Parks RW, Garden OJ (2004) The extent of resection influences outcome following hepatectomy for colorectal liver metastases. Eur J Surg Oncol 30:370–376PubMedCrossRef
10.
Lang BH, Poon RT, Fan ST, Wong J (2003) Perioperative and long-term outcome of major hepatic resection for small solitary hepatocellular carcinoma in patients with cirrhosis. Arch Surg 138:1207–1213PubMedCrossRef
11.
Castillo MH, Doerr RJ, Paolini N Jr, Cohen S, Goldrosen M (1989) Hepatectomy prolongs survival of mice with induced liver metastases. Arch Surg 124:167–169PubMed
12.
Doerr R, Castillo M, Evans P, Paolini N, Goldrosen M, Cohen SA (1989) Partial hepatectomy augments the liver’s antitumor response. Arch Surg 124:170–174PubMed
13.
Yokoyama H, Goto S, Chen CL, Pan TL, Kawano K, Kitano S (2000) Major hepatic resection may suppress the growth of tumours remaining in the residual liver. Br J Cancer 83:1096–1101PubMedCrossRef
14.
Rashidi B, An Z, Sun FX, Sasson A, Gamagammi R, Moossa AR, Hoffman RM (1999) Minimal liver resection strongly stimulates the growth of human colon cancer in the liver of nude mice. Clin Exp Metastasis 17:497–500PubMedCrossRef
15.
De Jong KP, Lont HE, Bijma AM, Brouwers MA, de Vries EG, van Veen ML, Marquet RL, Slooff MJ, Terpstra OT (1995) The effect of partial hepatectomy on tumor growth in rats: in vivo and in vitro studies. Hepatology 22:1263–1272PubMedCrossRef
16.
Panis Y, Ribeiro J, Chretien Y, Nordlinger B (1992) Dormant liver metastases: an experimental study. Br J Surg 79:221–223PubMedCrossRef
17.
Drixler TA, Borel Rinkes IH, Ritchie ED, van Vroonhoven TJ, Gebbink MF, Voest EE (2000) Continuous administration of angiostatin inhibits accelerated growth of colorectal liver metastases after partial hepatectomy. Cancer Res 60:1761–1765PubMed
18.
Delman KA, Zager JS, Bennett JJ, Malhotra S, Ebright MI, McAuliffe PF, Halterman MW, Federoff HJ, Fong Y (2002) Efficacy of multiagent herpes simplex virus amplicon-mediated immunotherapy as adjuvant treatment for experimental hepatic cancer. Ann Surg 236:337–342PubMedCrossRef
19.
Ono M, Tanaka N, Orita K (1986) Complete regression of mouse hepatoma transplanted after partial hepatectomy and the immunological mechanism of such regression. Cancer Res 46:5049–5053PubMed
20.
Schindel DT, Grosfeld JL (1997) Hepatic resection enhances growth of residual intrahepatic and subcutaneous hepatoma, which is inhibited by octreotide. J Pediatr Surg 32:995–997PubMedCrossRef
21.
Kollmar O, Schilling MK, Menger MD (2004) Experimental liver metastasis: standards for local cell implantation to study isolated tumor growth in mice. Clin Exp Metastasis 21:453–460PubMedCrossRef
22.
Menger MD, Lehr HA (1993) Scope and perspectives of intravital microscopy-bridge over from in vitro to in vivo. Immunol Today 14:519–522PubMedCrossRef
23.
Lehr HA, Leunig M, Menger MD, Nolte D, Messmer K (1993) Dorsal skinfold chamber technique for intravital microscopy in nude mice. Am J Pathol 143:1055–1062PubMed
24.
Menger MD, Laschke MW, Vollmar B (2002) Viewing the microcirculation through the window: some 20 years experience with the hamster dorsal skinfold chamber. Eur Surg Res 34:83–91PubMedCrossRef
25.
Vajkoczy P, Goldbrunner R, Farhadi M, Vince G, Schilling L, Tonn JC, Schmiedek P, Menger MD (1999) Glioma cell migration is associated with glioma-induced angiogenesis in vivo. Int J Dev Neurosci 17:557–563PubMedCrossRef
26.
Tsuchiya Y, Sawada S, Yoshioka I, Ohashi Y, Matsuo M, Harimaya Y, Tsukada K, Saiki I (2003) Increased surgical stress promotes tumor metastasis. Surgery 133:547–555PubMedCrossRef
27.
Picardo A, Karpoff HM, Ng B, Lee J, Brennan MF, Fong Y (1998) Partial hepatectomy accelerates local tumor growth: potential roles of local cytokine activation. Surgery 124:57–64PubMed
28.
Stoeckli SJ, Steinert H, Pfaltz M, Schmid S (2002) Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 24:345–349PubMedCrossRef
29.
de Jong IJ, Pruim J, Elsinga PH, Jongen MM, Mensink HJ, Vaalburg W (2002) Visualisation of bladder cancer using (11)C-choline PET: first clinical experience. Eur J Nucl Med Mol Imaging 29:1283–1288PubMedCrossRef
30.
Slooter GD, Marquet RL, Jeekel J, Ijzermans JN (1995) Tumour growth stimulation after partial hepatectomy can be reduced by treatment with tumour necrosis factor alpha. Br J Surg 82:129–132PubMedCrossRef
31.
Folkman J (2002) Role of angiogenesis in tumor growth and metastasis. Semin Oncol 29(Suppl 16):15–18PubMed
32.
Sckell A, Safabakhsh N, Dellian M, Jain RK (1998) Primary tumor size-dependent inhibition of angiogenesis at a secondary site: an intravital microscopic study in mice. Cancer Res 58:5866–5869PubMed
33.
Peeters CF, Westphal JR, de Waal RM, Ruiter DJ, Wobbes T, Ruers TJ (2004) Vascular density in colorectal liver metastases increases after removal of the primary tumor in human cancer patients. Int J Cancer 112:554–559PubMedCrossRef
34.
35.
Kollmar O, Scheuer C, Menger MD, Schilling MK (2006) Macrophage inflammatory protein-2 promotes angiogenesis, cell migration, and tumor growth in hepatic metastasis. Ann Surg Oncol 13:263–275PubMedCrossRef
36.
Kollmar O, Menger MD, Schilling MK (2006) Macrophage inflammatory protein-2 contributes to liver resection-induced acceleration of hepatic metastatic tumor growth. World J Gastroenterol 12:858–867PubMed
37.
Oe H, Kaido T, Mori A, Onodera H, Imamura M (2005) Hepatocyte growth factor as well as vascular endothelial growth factor gene induction effectively promotes liver regeneration after hepatectomy in Solt-Farber rats. Hepatogastroenterology 52:1393–1397PubMed
38.
Redaelli CA, Semela D, Carrick FE, Ledermann M, Candinas D, Sauter B, Dufour JF (2004) Effect of vascular endothelial growth factor on functional recovery after hepatectomy in lean and obese mice. J Hepatol 40:305–312PubMedCrossRef
39.
Yoon SS, Kim SH, Gonen M, Heffernan NM, Detwiller KY, Jarnagin WR, D’Angelica M, Blumgart LH, Tanabe KK, Dematteo RP (2006) Profile of plasma angiogenic factors before and after hepatectomy for colorectal cancer liver metastases. Ann Surg Oncol 13:353–362PubMedCrossRef
40.
Jaeschke H, Lemasters JJ (2003) Apoptosis versus oncotic necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 125:1246–1257PubMedCrossRef
Metadata
Title
Major but not minor hepatectomy accelerates engraftment of extrahepatic tumor cells
Authors
Kathrin Rupertus
Otto Kollmar
Claudia Scheuer
Bastian Junker
Michael D. Menger
Martin K. Schilling
Publication date
01-03-2007
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 1/2007
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-006-9054-6

Other articles of this Issue 1/2007

Clinical & Experimental Metastasis 1/2007 Go to the issue

Book Review

Book review: analyzing T cell responses

Original Paper

Isolation of a human gallbladder cancer cell clone with high invasive phenotype in vitro and metastatic potential in orthotopic model and inhibition of its invasiveness by heparanase antisense oligodeoxynucleotides

Research Paper

Clinical and radiological evaluation of patients with lytic, mixed and sclerotic bone metastases from solid tumors: is there a correlation between clinical status of patients and type of bone metastases?

Original Paper

Low expression of CD161 and NKG2D activating NK receptor is associated with impaired NK cell cytotoxicity in metastatic melanoma patients

Original Paper

Differential expression of hypoxia and (lymph)angiogenesis-related genes at different metastatic sites in breast cancer

Research Paper

Involvement of Hif-1 in desferrioxamine-induced invasion of glioblastoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits